フランスのサノフィ やスイスのロシュ・ホールディングなど複数のヨーロッ

フランスのサノフィ やスイスのロシュ・ホールディングなど複数のヨーロッパの製薬大手が、アメリカのバイオテクノロジー企業、インターミューンの買収に名乗りを上げている。



サノフィやロシュのほか、イギリスのグラクソ・スミスクラインやスイスのアクテリオンも買収案を提示している。
インタミューンの助言役は、ゴールドマン・サックス・グループとセンタービュー・パートナーズが務めている。
大手製薬メーカーは、医薬品のラインアップ増強を目指して、バイオテクノロジー企業の買収に注力している。年初からこうした買収は、約62億ドル規模と、2013年全体の約２倍となっている。

結果 (英語) 1:

Pharmaceutical giant Roche holding of Switzerland and Sanofi of France, several European have stepped up to the acquisitions of biotech companies in the United States, インターミューン.



Sanofi and Roche, as well as a present a proposed acquisition are GlaxoSmithKline of Britain and Switzerland's Actelion.
Advise Auditors of the インタミューン has served as Goldman Sachs Group and centers view partners.
Major pharmaceutical manufacturers areHas focused on the acquisitions of biotech companies constructing line-up of pharmaceutical products. From the beginning of the year and scale such acquisition is about 6200000000 dollars, has become two times overall in 2013.

結果 (英語) 2:

Pharmaceutical giant of Europe, such as multiple Roche Holding of Switzerland and Sanofi of France, have lined up biotechnology companies in the United States, the acquisition of Inter μ down. In addition to the Roche and Sanofi, Actelion and Swiss GlaxoSmithKline of the UK also have presented the proposed acquisition. The role of advice Intamyun, Center view Partners and Goldman Sachs Group are served. Towards a line-up enhancement of pharmaceuticals, major pharmaceutical manufacturers, is focused on the acquisition of biotechnology companies. These acquisitions have become and about $ 6.2 billion scale, with about twice the 2013 total from the beginning of the year.

結果 (英語) 3:

And France's Sanofi Swiss Roche holdings of European pharmaceutical and biotechnology companies of the United States, leading to the purchase of インターミューン. In addition it Sanofi and Roche, Britain's GlaxoSmithKline and Swiss active lions are presented. The role of Mu advice at the interface, and Goldman Sachs Group, center view partners. The pharmaceutical manufacturer.With the aim of enhancing product lineup, focusing on the acquisition of biotechnology companies. Such acquisitions since the beginning of the year, with about $62 billion in total, about twice as.